Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab (Emgality) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month.
Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function
(2018-11-20)
Läs artikeln på EMHAnews.com >>>
